Skip to main content
Premium Trial:

Request an Annual Quote

RainDance Technologies Closes $20M Series E Financing as Myriad Genetics Buys In

NEW YORK (GenomeWeb News) – RainDance Technologies said today that it has closed a $20 million Series E financing round and that Myriad Genetics has joined as a new strategic equity investor.

RainDance and Myriad earlier this month announced a multi-year commercial supply agreement under which Myriad has adopted RainDance's ThunderStorm system for targeted sequencing enrichment in a next-generation sequencing-based hereditary cancer panel that Myriad is developing.

All existing venture investors in RainDance, including Mohr Davidow Ventures, Quaker BioVentures, Alloy Ventures, Acadia Woods Partners, and Sectoral Asset Management, participated in the Series E round.

Lexington, Mass.-based RainDance said it will use the proceeds to drive global expansion of its products, including the ThunderStorm system and recently launched RainDrop digital PCR system for ultra-sensitive multiplexed quantitative detection of circulating nucleic acids.

In addition, the financing enables the company to substantially expand its commercial operations and manufacturing capacity, and to relocate its headquarters to a new facility in mid-2013, RainDance said.

"Myriad's strategic investment validates RainDance as an emerging leader in genetics research, positioning the company to build substantial value in the new era of personalized diagnostic medicine," Bill Ericson, general partner at Mohr Davidow Ventures and a member of the RainDance board of directors, said in a statement.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SAR-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.